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Abstract
Background: Leptin is a pleiotropic hormone whose mitogenic and angiogenic activity has been implicated in the
development and progression of several malignancies, including brain tumors. In human brain cancer, especially in
glioblastoma multiforme (GBM), leptin and its receptor (ObR) are overexpressed relative to normal tissue. Until
present, the potential of intratumoral leptin to exert proangiogenic effects on endothelial cells has not been
addressed. Using in vitro models, we investigated if GBM can express leptin, if leptin can affect angiogenic and
mitogenic potential of endothelial cells, and if its action can be inhibited with specific ObR antagonists. Leptin
effects were compared with that induced by the best-characterized angiogenic regulator, VEGF.
Results: We found that GBM cell lines LN18 and LN229 express leptin mRNA and LN18 cells secrete detectable
amounts of leptin protein. Both lines also expressed and secreted VEGF. The conditioned medium (CM) of LN18
and LN 229 cultures as well as 200 ng/mL pure leptin or 50 ng/mL pure VEGF stimulated proliferation of human
umbilical vein endothelial cells (HUVEC) at 24 h of treatment. Mitogenic effects of CM were ~2-fold greater than
that of pure growth factors. Furthermore, CM treatment of HUVEC for 24 h increased tube formation by ~5.5-fold,
while leptin increased tube formation by ~ 80% and VEGF by ~60% at 8 h. The mitogenic and angiogenic effects
of both CM were blocked by Aca 1, a peptide ObR antagonist, and by SU1498, which inhibits the VEGF receptor.
The best anti-angiogenic and cytostatic effects of Aca1 were obtained with 10 nM and 25 nM, respectively, while
for SU1498, the best growth and angiogenic inhibition was observed at 5 μM. The combination of 5 μM SU1498
and Aca1 at 25 nM (growth inhibition) or at 10 nM (reduction of tube formation) produced superior effects
compared with single agent treatments.
Conclusions: Our data provide the first evidence that LN18 and LN 229 human GBM cells express leptin mRNA
and might produce biologically active leptin, which can stimulate tube formation and enhance proliferation of
endothelial cells. Furthermore, we demonstrate for the first time that a peptide ObR antagonist inhibits
proangiogenic and growth effects of leptin on endothelial cells, and that the pharmacological potential of this
compound might be combined with drugs targeting the VEGF pathway.
Background
Leptin is an adipocyte-derived hormone that plays a
major role in the regulation of body weight by inhibiting
food intake and stimulating energy expenditure via
hypothalamic-mediated effects [1,2]. Besides its anorexi-
genic function, leptin regulates several physiological
processes, including angiogenesis [3-5]. Human
endothelium and primary cultures of human endothelial
cells express the leptin receptor, ObR [6,7]. In vitro stu-
dies demonstrated that leptin can stimulate growth and
survival of endothelial cells as well as induce their
migration and organization into capillary-like tubes
[6-9]. In vivo, leptin is able to induce complete angio-
genesis in the chick choriallantoic membrane assay [6]
and disc angiogenesis system [10] as well as promote
neovascularization in corneas of normal, but not ObR-
deficient Zucker fa/fa, rats [7] or normal mice [11]. In
addition to its own effects, leptin synergizes with
* Correspondence: surmacz@temple.edu
1Sbarro Institute for Cancer Research and Molecular Medicine, Biotechnology
Center, Temple University, 1900 N 12th street, Philadelphia, PA 19122, USA
Full list of author information is available at the end of the article
Ferla et al. BMC Cancer 2011, 11:303
http://www.biomedcentral.com/1471-2407/11/303
© 2011 Ferla et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.vascular endothelial growth factor (VEGF) and basic
fibroblastic growth factor (bFGF) in the stimulation of
blood vessel growth and vascular permeability [11].
Proangiogenic and mitogenic functions of leptin have
been implicated in development and progression of dif-
ferent neoplasms. Multiple studies demonstrated that
leptin is able to stimulate survival [12-14], proliferation
[15-17], migration and invasiveness [18-22] of several
cancer cell types. In addition, leptin might also contri-
bute to tumor neoangiogenesis. Exposure of cancer cells
to hypoxic conditions and/or elevated concentrations of
growth factors, such as insulin, can activate production
of endogenous leptin, raising intratumoral levels of this
hormone [23-28]. Proangiogenic effects of leptin can be
further potentiated by its ability to upregulate the
expression of other angiogenic factors, such as VEGF,
bFGF, interleukin 1-b, and leukemia inhibitory factor in
cancer cells [18,29-31].
New evidence suggests leptin can be involved in the
development of brain tumors [13,22,32-35]. Initial work
documented the presence of leptin and ObR transcripts
in various human intracranial tumors [34]. Other
reports demonstrated that rat glioma tissues and cell
lines express leptin mRNA [33,36], and that in rat C6
cells leptin can increase survival [13,32,33] and enhance
migration and invasion of these cells [22].
We recently demonstrated that both leptin and ObR
proteins are overexpressed in human brain tumors rela-
tive to normal brain tissue, and that leptin/ObR expres-
sion levels positively correlate with the degree of
malignancy. The highest levels of leptin and ObR were
found in glioblastoma multiforme (GBM), where both
proteins were coexpressed with activated forms of ser-
ine/threonine protein kinase B (Akt) and signal transdu-
cer and activator of transcription 3 (STAT3).
Interestingly, the greatest amounts of all these proteins
were detected in perivascular areas and in groups of
cells invading the adjacent brain parenchyma [35].
In ObR-positive glioblastoma cell lines LN18 and
LN229, leptin stimulates cell proliferation and induces
STAT3 and Akt pathways as well as inactivates the cell
cycle suppressor Rb [35]. Furthermore, leptin-dependent
phosphorylation of STAT3 in LN18 and LN229 cells
can be inhibited with Aca1, a novel ObR antagonist [37].
Until present, no studies addressed the potential
angiogenic role of leptin in human GBM. Considering
that glioma progression from lower-grade tumors to
highly malignant GBM is characterized by increasing
intratumoral expression of leptin [35] as well as induc-
tion of angiogenesis [38,39], we investigated angiogenic
properties (induction of tube formation) of GBM-
derived leptin using endothelial cell models and specific
ObR antagonists. The effects were compared with that
produced by VEGF, the best characterized angiogenic
factor.
Results
Conditioned media of GBM cultures stimulate tube
formation and growth of human vascular endothelial cells
The survival and expansion of brain tumor cells is asso-
ciated with increased expression and secretion of proan-
giogenic factors [38-40]. New vessel formation requires
that endothelial cells migrate into the extracellular
matrix and then adhere to each other to create a lumen
[38,41]. To examine the effect of GBM cell line-derived
conditioned media (CM) on this process, we employed
an in vitro model of angiogenesis using human umbilical
vein endothelial cells (HUVEC). HUVEC have the ability
to invade a collagen I matrix and to form a network of
tube-like structures [9,41,42].
W ef i r s tt e s t e di fc o n d i t i o n e dm e d i a( C M )d e r i v e d
from our GBM cell lines can induce proliferation and
tube formation of HUVEC. HUVEC were cultured for
24 h on collagen I in presence of CM from LN18 and
LN229 cells mixed 1:1 with HUVEC growth medium.
The ability of HUVEC to organize into tube-like struc-
tures was scored as the number of enclosed spaces (ES).
Incubation with LN18- and LN229-derived CM
increased the number of ES by 5.7- and 5.3-fold, respec-
tively, relative to negative control (Figure 1A). Moreover,
relevant morphological changes in endothelial cells were
noted. In response to treatment with both CM, endothe-
lial cells become elongated, exhibited extended protru-
sions, and were aligned along the perimeter of the
enclosed spaces. In contrast, in the negative control
experiment, only a minimal invasion and formation of
ES was noticeable (Figure 1B).
Endothelial cell proliferation is another key character-
istic of the angiogenic process. A 24 or 48 h treatment
with GBM-derived CM significantly increased the
growth of HUVEC. In particular, LN18 and LN229-
derived CM enhanced cell proliferation by ~ 26% and ~
44% at 24 h, and ~ 47% and ~ 69% at 48 h, respectively
(Figure 1C). All the above data suggest that LN18 and
LN229 CM contain factors able to induce in vitro
endothelial cell proliferation and differentiation.
Analysis of leptin and VEGF mRNA and protein
expression in LN18 and LN229 cells
The expression of leptin mRNA and protein by human
breast and colorectal cancer cells and rat glioblastoma
cultures has been documented previously [24,27,33,43].
The synthesis of VEGF by GBM and other cancer cells
has also been described [44-46]. Here we studied if
LN18 and LN229 cell lines express leptin and VEGF
mRNAs and proteins (Figure 2).
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lines, however, a cell-specific dynamic of expression was
noted for both transcripts. At basal conditions, the levels
of leptin mRNA were significantly lower (8.3-fold and
5.2-fold in LN18 and LN229 cells, respectively) than
that of VEGF mRNA. In both cell lines, leptin mRNA
levels were higher at 48 h than at 24 h in SFM. How-
ever, in LN229 cells, leptin mRNA levels at 24 h were
~5-fold greater than that in LN18 cells. On the other
hand, after 48 h in SFM, leptin transcripts detected in
LN229 cells were significantly lower than that in LN18
cells. Under our experimental conditions, LN18 cells
showed an approximately 18-fold increase of leptin
mRNA levels after 48 h of serum-starvation (Figure 2A).
Less variability was observed for VEGF mRNA expres-
sion. VEGF mRNA levels increased in a time-dependent
manner and were more elevated in LN18 cells than in
LN229 cells at both time points (Figure 2A).
Next, we investigated the amounts of secreted leptin
and VEGF in CM derived from both GBM cell lines
(Figure 2B). At 24 h, we found ELISA-detectable levels
of both leptin and VEGF only in LN18 cells, but not in
LN229 cells. At 48 h, amounts of both proteins
increased in LN18 CM, while in LN229 CM, leptin was
undetectable and VEGF was present at very low levels
(Figure 2B).
Figure 2 GBM cells express leptin and VEGF. A) The abundance
of leptin and VEGF mRNA was studied with qRT-PCR as described
in Materials and Methods. The graphs represent leptin and VEGF
mRNA levels relative to LN18 levels in SFM (= 1) ± SD. B) Leptin
and VEGF secreted protein levels were measured in LN18 and
LN229 CM by ELISA, as described in Materials and Methods. The
values represent pg/mL per 9 × 10
6 LN18 cells and 6 × 10
6 LN229
cells ± SD.
Figure 1 CM derived from GBM cell lines LN18 and LN229
enhances angiogenic and mitogenic capabilities of HUVEC. A)
Tube-like formation assay was performed in SFM or LN18 and
LN229-derived CM mixed (1:1) with VCBM for 24 h, as described in
Materials & Methods. The graph shows relative % increase of ES
formed by HUVEC with the number in SFM taken as = 100%.
Columns, mean of at least three independent experiments done in
triplicates; bars, SE. ** P < 0,001 (vs. control SFM: VCBM). B)
Representative phase contrast pictures (magnification 10×) of
HUVEC in vitro angiogenesis in response to LN18 or LN229 CM for
24 h. SFM:VCBM treatment was used as control. The cultures were
evaluated and photographed as described in Materials and
Methods. C) HUVEC were grown in SFM:VCBM or LN18 and LN229-
derived CM mixed (1:1) with VCBM for 24 or 48 h. The graph
represents relative growth increase with SFM:VCBM taken as
reference (0%). Columns, mean of at least three independent
experiments done in triplicates; bars, SE. * P < 0,05 and ** P < 0,001
(vs. control SFM:VCBM).
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signaling in HUVEC. Inhibitors of ObR and VEGFR block
these effects
HUVEC are capable to respond to both leptin and
VEGF, as they express various isoforms of ObR, includ-
ing the long signaling form, ObRb, [6,7] as well as the
VEGF receptor (VEGFR) [47,48]. As previously reported,
leptin can stimulate tube-like structures in vitro [6-9].
To investigate the mechanism of this effect, we used
Aca1, a potent ObR antagonist, developed in our labora-
tories and proven to inhibit leptin signaling in LN18
and LN229 cells [37]. Treatment of HUVEC with 100
ng/mL leptin for 8 h produced ~ 80% increase in ES
formation compared with untreated cells (Table 1 and
Figure 3A). Addition of Aca1 consistently counteracted
this leptin-dependent effect. At the lowest concentration
used (10 nM) Aca1 completely reverted the leptin-
induced ES increase, whereas a slight reduction of the
ES number vs. control was observed in the presence of
Aca1 at 25 and 50 nM concentrations. Notably, Aca1
alone did not affect the number of ES relative to con-
trol, except for a slight decrease at the highest concen-
tration, suggesting its specific activity towards ObR in
presence of leptin (Table 1 and Figure 3A).
In parallel, we treated HUVEC with 50 ng/mL VEGF,
either alone or in presence of SU1498, a potent inhibitor
of VEGFR2 [49]. VEGF increased by ~ 60% the number
of ES, and this effect was antagonized by SU1498 in a
dose-dependent manner, with the best response noted
at 5 μM (Table 1 and Figure 3A).
Next, we assessed the proliferative response of HUVEC
to leptin in the presence or absence of ObR antagonist.
Leptin at 200 ng/mL increased the growth of HUVEC by
25% relative to control (untreated cells) (Figure 3B). The
addition of Aca1 interfered with leptin-induced prolifera-
tion in a dose-dependent manner. In particular, Aca1 at
25 nM completely and significantly abolished leptin mito-
genic effects (Figure 3B), while the antagonist at the high-
est concentration (50 nM) produced cytotoxic effects,
significantly more pronounced in the absence of leptin.
However, no great influence on cell growth was detected
in HUVEC treated with Aca1 alone at 10 and 25 nM.
The parallel experiments with VEGF demonstrated
that 50 ng/mL VEGF stimulated HUVEC proliferation
by 27% relative to untreated cells. SU1498 reduced this
effect in a dose dependent manner. 5 μM SU1498 totally
blocked VEGF effects, while higher concentrations of
the inhibitor were cytotoxic (Figure 3B).
To investigate the mechanism of Aca1 and SU1498
interference with leptin or VEGF effects on HUVEC, we
studied if the antagonists are able to inhibit ligand-
induced intracellular STAT3 signaling. The induction of
S T A T 3b yl e p t i no rV E G Fi nH U V E Cw a sp r e v i o u s l y
reported [7,50]. We confirmed that leptin activates
STAT3 in these cells and found that Aca1 is able to sig-
nificantly reduce leptin-dependent STAT3 phosphoryla-
tion (Figure 3C). Similarly, VEGF activated STAT3, and
SU1498 reduced STAT3 phosphorylation in VEGF-trea-
ted HUVEC (Figure 3C).
These above data suggest that Aca1 and SU1498 are
suitable to evaluate the specific contributions of leptin
and VEGF in angiogenic and mitogenic effects of CM
derived from GBM cell cultures.
Effects of ObR and VEGFR inhibitors on CM-induced tube
formation and growth of HUVEC
Our results demonstrated detectable amounts of leptin
and VEGF mRNAs in LN18 CM, suggesting that these
cells might produce leptin and VEGF proteins. In order
to assess if the observed effects of LN18 CM on tube
formation and growth of HUVEC can be ascribed to the
activity of leptin and VEGF, we used Aca1 and SU1498,
specific antagonists of ObR and VEGFR2, respectively.
The addition of Aca1 to LN18 CM significantly
reduced the ability of HUVEC to reorganize into ES.
Specifically, 10 nM and 25 nM Aca1 inhibited CM-
dependent ES formation by 38 and 45%, respectively.
This effect was not improved by increasing the concen-
tration of Aca1 up to 50 nM (Table 2 and Figure 4A).
Similarly, treatment with SU1498 blocked CM-induced
ES formation by 45 and 75% at 1 and 5 μM, respectively
(Table 2 and Figure 4A).




Leptin 178.0 ± 3.0
Leptin + Aca1 10 nM 90.0 ± 1.0
Leptin + Aca1 25 nM 79.0 ± 6.5
Leptin + Aca1 50 nM 72.0 ± 32.5
Aca1 10 nM 103.5 ± 12.0
Aca1 25 nM 90.0 ± 1.0
Aca1 50 nM 68.0 ± 4.0
VEGF 160.0 ± 13.0
VEGF + SU1498 1 μM 121.0 ± 30.0
VEGF + SU1498 5 μM 98.0 ± 14.5
VEGF + SU1498 10 μM 73.0 ± 6.0
SU1498 1 μM 100.5 ± 23.0
SU1498 5 μM 91.0 ± 1.4
SU1498 10 μM 60.0 ± 10.0
ObR and VEGFR inhibitors counteract this effect.
Number of ES after treatment with 100 ng/mL leptin and/or Aca1Free 10, 25
and 50 nM or with 50 ng/mL VEGF and/or SU1498 1, 5 and 10 μM was scored
as described in Materials and Methods. Untreated cells were taken as control
(100%). Tube-like formation assay was performed for 8 h in VCBM. Means ±
SD are shown.
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Page 4 of 11Figure 3 Leptin and VEGF enhance angiogenesis and growth of HUVEC. ObR and VEGFR inhibitors counteract these effects. A)
Representative phase contrast images (magnification 10×) of ES formed by HUVEC treated with 100 ng/mL leptin and/or with Aca1 or with 50
ng/mL VEGF and/or with SU1498 or left untreated (control) for 8 h. B) HUVEC growing in VCBM were treated for 24 h with 200 ng/mL leptin
and/or Aca1 10, 25 or 50 nM or with 50 ng/mL VEGF and/or or with SU1498 1 and 5 μM or left untreated (control). The graph represents
relative growth increase with untreated cells taken as reference (0%). Columns, mean of at least three independent experiments done in
triplicates; bars, SE. * P < 0,05 and ** P < 0,01 (Leptin or VEGF vs. untreated cells, leptin + Aca1 vs. leptin or VEGF + SU1498 vs. VEGF). C) HUVEC
were pretreated for 1 h with ObR or VEGFR inhibitors and then treated with 200 ng/mL leptin or 50 ng/mL VEGF for 15 min or left untreated as
described in Materials and Methods. Levels of pSTAT3 and total STAT3 (~88 kDa) were determined by WB in 50-70 μg of total cell lysates using
specific Abs, as described in Material and Methods. Arrows indicate the position of 105 kDa molecular weight marker.
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with different doses of SU1498 produced greater ES
inhibition than that seen with individual antagonists.
Specifically, 10 nM Aca1 plus 1 μM SU1498 reduced ES
formation by 65%, while 10 nM Aca1 with 5 μM
SU1498 blocked ES organization by 90% (Table 2).
We also evaluated the effect of the antagonists on
LN18 CM-dependent growth of HUVEC cultures (Fig-
ure 4B). Aca1 counteracted the effect on cell prolifera-
tion induced by LN18 CM in a dose-dependent manner.
The greatest inhibition of growth was observed at 48 h
when Aca1 at 10, 25, and 50 nM reduced the mitogenic
effects of CM by 14, 22, and 31%, respectively (Figure
4B). SU1498 at 5 μM reduced LN18 CM-mediated
growth of HUVEC by 20%, while no significant effect
was observed with SU1498 1 μM and higher concentra-
tions of the antagonists were slightly cytotoxic (Figure
4B and data not shown).
The combination of 25 nM Aca1 and 5 μM SU1498
reduced HUVEC proliferation by 45%, demonstrating
the significant improvement over single inhibitor treat-
ments. However, addition of Aca1 to 5 μM SU1498 only
minimally increased cytostatic effects, while the combi-
nation of 50 nM Aca1 and 5 μ SU1498 did not improve
t h ee f f i c a c yo fs i n g l et r e a tments (Figure 4B). These
results suggested that LN18 CM affects, at least in part,
HUVEC growth and tube formation through ObR and
VEGFR2-dependent mechanisms, both of which can be
targeted by specific molecular antagonists.
Discussion
Malignant astrocytic gliomas, especially GBMs, are char-
acterized by poor prognosis and low patient survival
rates [51]. Although these tumors rarely metastasize,
they almost always recur locally because of their inher-
ent tendency for diffuse infiltration [52,53]. In particular,
a strong induction of angiogenesis marks the transition
from lower-grade tumors to more aggressive and lethal
GBMs [39]. Therefore, despite advanced clinical
approaches with surgery, radiotherapy and chemother-
apy [54-56], inhibition of angiogenesis might represent a
key strategy in the treatments of gliomas.
Recent preclinical data demonstrated that anti-VEGF
agents (e.g. ceradinib, bevacizumab) can transiently nor-
malize the elevated permeability and interstitial pressure
of brain tumor vessels, enhancing in this way the pene-
tration of concurrently administered drugs
[38-40,52,57,58]. Besides direct VEGF or VEGFR2 inhi-
bition for glioblastoma, clinical studies are being con-
ducted or planned with agents targeting further
downstream or alternative pathways frequently altered
in brain tumors, including the mTOR/Akt and EGFR
pathways [39].
Nevertheless, the success with the existing compounds
in the management of brain tumors is very limited. It is
likely that combination of therapeutic agents targeting
different pathways, especially angiogenic pathways, will
produce more significant clinical effects. In this context,
we focused on leptin, a multifunctional hormone that is
able to exert angiogenic activity in different in vitro and
in vivo model systems [6-8,10,11,18,29-31].
Leptin has been implicated in neoplastic processes,
especially in obesity-related cancers, where the hormone
has been shown to stimulate cancer cells growth, survi-
val [12,14,15,28,59], resistance to different chemothera-
peutic agents [60,61] as well as migration, invasion and
angiogenesis [18-21,29,62].
In the central nervous system (CNS) leptin regulates
several physiological brain functions, including hippo-
campal and cortex-dependent learning, memory and
cognitive function, neuronal stem cells maintenance,
and neuronal and glial development [63,64]. In addi-
tion, recent research suggests the potential role of
this hormone in the progression of brain tumors [35].
We previously demonstrated that the expression of
leptin and ObR in human brain tumor tissues corre-
lates with the degree of malignancy, and the highest
levels of both markers are detected in GBM. Specifi-
cally, and in relevance to the present study, leptin and
ObR were expressed in over 80% and 70% of 15 GBM
tissues analyzed [35]. Other studies demonstrated lep-
tin mRNA expression in rat glioma tissues and cell
lines [33,36]. Because leptin and ObR in human brain
tumors are commonly coexpressed, leptin effects are
likely to be mediated by autocrine pathways. Using in
vitro models, we found that LN18 and LN229 ObR-
positive GBM cells respond to leptin with cell growth
and induction of the oncogenic pathways of Akt and
STAT3, as well as inactivation of the cell cycle sup-
pressor Rb [35]. However, the potential role of intra-
tumoral leptin in glioma progression, especially in the
Table 2 Effects of Aca1 and SU1498 on LN18 CM-induced
ES formation by HUVEC
Conditions ES (%)
LN18 CM 100.0
LN18 CM + Aca1 10 nM 62.0 ± 11.5
LN18 CM + Aca1 25 nM 55.0 ± 1.4
LN18 CM + Aca1 50 nM 52.0 ± 8.5
LN18 CM + SU1498 1 μM 55.0 ± 5.5
LN18 CM + Aca1 10 nM + SU1498 1 μM 35.0 ± 7.5
LN18 CM + SU1498 5 μM 25.0 ± 3.5
LN18 CM + Aca1 10 nM + SU1498 5 μM 10.2 ± 3.2
Tube-like formation assay was performed in LN18-derived CM mixed (1:1) with
VCBM, containing or not Aca1 and/or SU1498 for 24 h, as described in
Materials and Methods. The table shows the relative increase of ES formation
(%), with LN18 CM taken as reference (100%). Means ± SD are shown.
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Here we investigated if the hormone can be expressed
by human GBM cell cultures, if it can affect angio-
genic and mitogenic potential of endothelial cells, and
if its action can be inhibited with specific ObR
antagonists. The results were compared with that
induced by the best-characterized angiogenic regula-
tor, VEGF.
Our data demonstrated that conditioned media pro-
duced by both LN18 and LN229 GBM cell lines
enhanced HUVEC tube formation and proliferation.
These data are in agreement with previous reports
showing that GBM cultures express VEGF and other
factors that can induce HUVEC angiogenesis [65-67].
We found variable levels of leptin and VEGF mRNA
in LN18 and LN229 cell lines cultured under SFM con-
ditions. In general, the abundance of VEGF transcripts
in both cell lines was significantly greater that that of
leptin mRNA. Secreted leptin and VEGF proteins were
f o u n di nL N 1 8C M ,w h i l ei nL N 2 2 9C M ,l e p t i nw a s
undetectable and VEGF was present at low levels. The
reason for lack or minimal presence of these proteins in
LN229 CM, despite quite prominent expression of the
cognate mRNAs, is unclear. It is possible that it is due
to limited sensitivity of ELISA assays unable to detect
proteins below the minimal threshold level. We specu-
late that LN229 cells might produce proteins binding
VEGF and leptin, thereby converting them into ELISA-
Figure 4 Aca1 and SU1498 inhibit angiogenic and mitogenic effects of LN18 CM. A) Representative phase contrast images (magnification
10×) of ES formed by HUVEC grown for 24 h in SFM or LN18-derived CM containing or not 50 nM Aca1 and/or 5 μM SU1498. B) HUVEC were
grown for 48 h in CM mixed (1:1) with VCBM, containing 10, 25 or 50 nM Aca1 and/or 5 μM SU1498 as described in Materials and Methods. The
graph represents relative growth increase, with CM taken as reference (100%). Columns, mean of at least three independent experiments done
in triplicates; bars, SE. * P < 0,05 and ** P < 0,01 (CM + Aca1 or CM + SU1498 5 μM vs. CM alone, CM + Aca1/SU1498 5 μM vs. CM + Aca1 and
CM + SU1498 5 μM).
Ferla et al. BMC Cancer 2011, 11:303
http://www.biomedcentral.com/1471-2407/11/303
Page 7 of 11unrecognizable complexes. Alternatively, LN229 CM
might contain proteases degrading the angiogenic
proteins.
In order to clarify if LN18 CM angiogenic and mito-
genic effects are, at least in part, related to leptin
secreted by these cells, we used specific ObR inhibitor,
A c a 1 .W eh a v ep r e v i o u s l yd e m o n s t r a t e dt h a tt h i s
antagonist binds ObR in vitro, inhibits leptin-induced
signaling at pM-low nM concentrations in different
types of cancer cells, including LN18 and LN229 cells,
while its derivative Allo-aca is able to reduce the growth
of hormone-receptor positive breast cancer xenografts
and enhance survival of animals bearing triple-negative
breast cancer xenogranfts [37,68]. Furthermore, All-aca
also inhibits leptin activity in some animal models of
rheumatoid arthritis [69]. Interestingly, we also detected
CNS activity of Aca1, suggesting that the peptide has
the ability to pass the blood-brain barrier [37,68,70].
In the present work, we found that Aca 1 can abrogate
leptin-induced tube formation and mitogenesis of
HUVEC at 10 and 25 nM concentrations, respectively.
Notably, the peptide alone did not affect cell growth
and did not modulate the ability of HUVEC to organize
into tube-like structures, suggesting that it acts as a
competitive antagonist of ObR. Next, we demonstrated
that Aca1 at 10-50 nM concentrations was able to
antagonize tube formation and growth effects of LN18
CM. The anti-angiogenic effects of 25 and 50 nM Aca1
were comparable to that obtained with 1 μM SU1498,
while anti-mitotic activity of 25 and 50 nM Aca1 was
comparable to the action of 5 μM SU1498. Furthermore,
the combination of low doses of Aca1 (10 nM) and
SU1498 (1 or 5 μM) produced greater inhibition of CM
effects than that obtained with single antagonists.
Interestingly, Aca1 or SU1498 appeared to differen-
tially affect the morphology of HUVEC cultures. While
Aca1 reverted the organized ES phenotype to the initial
appearance of dispersed cell culture, SU1498 disrupted
ES structures, reduced cell-matrix attachment and
induced cell aggregation. This might suggest that the
inhibitors affect different cellular mechanism and that
leptin and VEGF control HUVEC biology through dif-
ferent pathways.
Taken together, our data indicated that GBM cells are
able to induce endothelial cells proliferation and organi-
zation in capillary-like structures through, at least in
part, leptin- and VEGF-dependent mechanisms. Thus,
leptin might contribute to the progression of GBM
through the stimulation of new vessel formation. Leptin
action can be direct or indirect, through upregulation of
VEGF expression. Indeed, we observed that leptin can
transiently increase VEGF mRNA levels in GBM cells at
6-8 h of treatment (data not shown). In this context,
effective reduction of tube formation and mitogenic
activity of endothelial cells by ObR antagonist, especially
in the combination with VEGFR2 inhibitor, suggest that
targeting both leptin and VEGF pathways might repre-
sent a new therapeutic strategy to treat GBM.
Conclusions
Our previous work demonstrated that leptin and ObR
are significantly overexpressed in human GBM tissues
and the presence of both biomarkers correlates with
tumor grade. Current data suggest that human GBM
cells in culture have the ability produce biologically
active leptin that can induce growth and pro-angiogenic
effects in endothelial cells. These effects of leptin can be
blocked with a novel ObR antagonist, Aca1. The phar-
macological potential of this compound might be com-
bined with novel drugs targeting the VEGF pathway.
Methods
Cell lines and growth conditions
All cell lines were obtained from ATCC (Manassas, VA).
Glioblastoma cell lines LN229 and LN18 were cultured
in low glucose-Dulbecco modified Eagle’sM e d i u m
(DMEM) (Cellgro Mediatech, Manassas, VA) containing
5% fetal bovine serum (Cellgro Mediatech, Manassas,
VA). Human Umbilical Vein Endothelial Cells (HUVEC)
were maintained in Vascular Cell Basal Medium
(VCBM), supplemented with the Vascular Cell Growth
kit BBE, both purchased from ATCC.
ObR and VEGFR inhibitors
The ObR antagonist, Aca1, is a short leptin-based pepti-
domimetic (H-Thr-Glu-Nva-Val-Ala-Leu-Ser-Arg-Aca-
NH2) whose sequence is based on leptin/ObR binding
site III. The process of peptide design, screening and
development has been reported by us before [37,71,72].
The efficacy of Aca1 and its derivative Allo-aca in vitro
and in vivo has been described in detail previously
[37,68]. SU1498, the antagonist of VEGFR2 was pur-
chased from Calbiochem, USA.
Conditioned medium (CM) preparation
Subconfluent LN18 and LN229 cell cultures were placed
in SFM (DMEM low glucose supplemented with 0.42 g/
mL bovine serum albumin, 1 μMF e S O 4 and 2 mM L-
glutamine) for 24 or 48 h, and then the CM was col-
lected, centrifuged at 2000 rpm for 5 min, and the
supernatants frozen at -80°C until use. The number of
cells in cultures used for CM production was counted.
Proliferation assays
HUVEC (1.5 × 10
4) were plated in 24-well plates and
allowed to adhere overnight in the growth medium.
Then the cells were treated for 24 h with either 200 ng/
mL leptin (R&D Systems, Minneapolis, MN) in presence
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VEGF in presence or absence of 1 or 5 μM SU1498 or
left untreated as control. For assays with GBM-derived
CM, HUVEC were seeded as described above, and
allowed to adhere overnight. Then the culture medium
was replaced with SFM (negative control) or CM mixed
with HUVEC growth medium (1:1) with or without
Aca1 (10, 25, 50 nM) and/or SU1498 5 μM. At conclu-
sion of proliferation assays, the cells were counted
under the microscope with trypan-blue exclusion. Each
experiment was performed in triplicate and repeated at
least three times.
In vitro tube formation assay
The tube formation assay was based on procedures
described by Park et al and Feng et al. [9,42]. For the
tube-like formation assays, 24-wells plates were coated
with 300 μl of 2 mg/mL collagen I (BD Biosciences,
Bedford, MA) prepared according to manufacturer’s
instructions. Where appropriate, leptin (100 ng/mL)
and/or Aca1 (10, 25, 50 nM) and/or VEGF (50 ng/ml)
and/or SU1498 (1, 5, 10 μM) were added to the collagen
I prior to polymerization. Then, 8 × 10
4 of HUVEC sus-
pended in 1 ml of HUVEC growth medium containing
various treatments were plated on the top of the col-
lagen layers. For tube formation assay performed with
CM, HUVEC were seeded in 1 ml of SFM (negative
control) or GBM-derived CM mixed (1:1) with HUVEC
growth medium, containing or not Aca1 and/or
SU1498. After 8 and 24 h for assays performed in
HUVEC growth medium and CM, respectively, the
HUVEC were stained with Giemsa (diluted 1:10 in dis-
tilled water) for 15 min. The number of ES, representing
tube-like formation capability of HUVEC, was scored by
two observers in 10 fields using a contrast phase micro-
scope (Olympus CKX FA) with 10× magnification.
Quantitative Real Time PCR (qRT-PCR)
Subconfluent cultures of LN18 and LN229 cells were
placed in SFM for 24 and 48 h, and then RNA was iso-
lated using Trizol reagent (Invitrogen), according to
manufacturer’s instructions. A total of 10 μgo fR N A
was reverse transcribed in 100 μl of reaction volume
using the High-Capacity cDNA Archive (Applied Biosys-
tems, Foster City, CA) according to the manufacturer’s
protocol. Seven μl of the RT products were used to
amplify leptin and VEGF sequences using the
Hs00174877_m1 and the Hs00900054_m1 TaqMan
probes (Applied Biosystems), respectively. To normalize
qRT-PCR reactions, parallel reactions were run on each
sample for b-actin. Changes in the target mRNA con-
tent relative to b-actin mRNA were determined using a
comparative CT method to calculate changes in CT,
and ultimately fold and percent change. An average CT
value for each RNA was obtained for replicate reactions.
Western blot (WB) analysis
Subconfluent cultures (80% of density) of HUVEC were
placed in SFM for 1 h, pretreated for 1 h with ObR or
VEGFR inhibitors, and then treated with 200 ng/mL lep-
tin or 50 ng/mL VEGF for 15 min or left untreated.
Next, the cells were lysed in a buffer containing 1%
NP40, 50 mM HEPES pH 7.5, 250 mM NaCl, 5 mM
EDTA pH 8.0, 0.1% SDS, protease inhibitors 1× (Com-
plete Mini EDTA-free protease inhibitors, Roche, Ger-
many) and phosphatase inhibitors (10 mM Na3Vo4 and
50 mM NaF). The expression of proteins was analyzed
in 50-70 μg of total cell lysates. The following antibodies
(Ab) were used for WB: for phospho-STAT3, STAT3
Tyr705, D3A7 mAb, 1:1000 and for total STAT3,
STAT3 79D7 mAb, 1:1000, all purchased from Cell
Signaling, MA, USA; for glyceraldehyde-3-phosphate
dehydrogenase 6C5 (GAPDH), 1:1000 (Santa Cruz Bio-
technology, CA, USA).
Leptin and VEGF detection by ELISA
CM obtained from 2-3 plates of 80% confluent GBM
cultures was collected, as described above. The concen-
trations of leptin and VEGF in CM (obtained using WB
lysis buffer without 0.1% SDS) were measured using lep-
tin and VEGF Human Quantikine ELISA Kits (R&D
Systems). The standard curve was created using purified
leptin or VEGF. The concentrations of leptin or VEGF
are expressed as pg/mL/9 × 10
6 LN18 cells and pg/mL/
6×1 0
6 LN229 cells. All detected concentrations were
within the range of the standard curve. All measure-
ments were done in triplicate and the experiments were
repeated three times.
Statistical analysis
All experiments were done at least in triplicates and
data analyzed by Student’s t-test. Differences with p
values of ≤ 0.05 were considered significant.
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